ArticleCardiovascular diabetology. Endocrinology reports2025
Effect of cabergoline on the management of diabetes mellitus: a systematic review and meta-analysis.
Article in Cardiovascular diabetology. Endocrinology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus (DM) is one of the oldest diseases known to man. Type 2 diabetes is characterized by relative insulin deficiency due to pancreatic beta cell dysfunction and insulin resistance in target organs, which will reach 629 million people by 2045. On the other hand, dopamine and dopaminergic signals control some metabolic pathways. Cabergoline is a long-acting dopamine agonist with a high affinity for dopamine receptors. MATERIALS AND
methodsIn the current systematic review and Meta-analysis, all research published in PubMed, Google Scholar, and Scopus databases investigating the effect of cabergoline on the control of fasting plasma glucose (FPG), postprandial glucose (PPG), and HbA1c has been included. The overall certainty of the evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation approach. Comprehensive Meta-analysis Software was used for the statistical analyses using a random-effects model.
resultsA total of six articles (206 participants) were found from the mentioned databases. Data were extracted from six trials. Pooled Meta-analysis revealed that cabergoline significantly reduced FPG (SMD = -2.058; 95% CI: -3.269, -0.848), PPG (SMD = -1.786; 95% CI: (-3.035, -0.539), and HbA1c (SMD = -1.282; 95% CI: -2.283), but the analysis had extremely high heterogeneity (P-value-heterogeneity = 0.000).
conclusionThe results indicate that cabergoline may positively affect the control of type 2 diabetes, as almost all of the six reviewed articles revealed a significant reduction in FPG, PPG, and HbA1c. However, further studies with a larger sample size and on type 1 and 2 DM are required to confirm these results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.